Sector: Healthcare | Industry: Biotechnology & Medical Research |
Company Contact | |
Address: | 7824 51 Ave NW EDMONTON AB T6E 6W2 |
Tel: | 1-833-4758247 |
Website: | https://www.ceapro.com |
IR: | See website |
Key People | ||
Gilles R. Gagnon Chief Executive Officer, Director | Stacy Prefontaine Chief Financial Officer |
Business Overview |
Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner. |
Financial Overview |
For the nine months ended 30 September 2023, Ceapro Inc revenues decreased 49% to C$8M. Net loss totaled C$2.6M vs. income of C$4.6M. Revenues reflect United states segment decrease of 63% to C$3.5M, China segment decrease of 97% to C$40K. Net loss reflects Legal increase from C$20K to C$1.5M (expense), Board of Directors compensation increase from C$254K to C$696K (expense). |
Employees: | 12 as of Dec 31, 2001 |
Reporting Currency: | Canadian Dollars |
Enterprise value: | $7.54M as of Sep 30, 2023 |
Annual revenue (TTM): | $11.30M as of Sep 30, 2023 |
EBITDA (TTM): | -$1.81M as of Sep 30, 2023 |
Net annual income (TTM): | -$2.70M as of Sep 30, 2023 |
Free cash flow (TTM): | -$1.29M as of Sep 30, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 78,293,177 as of Sep 30, 2023 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |